A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
← catalyst calendarNCT05767736 · readout in 2,296 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
10,500estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-08 | actual | When the study began enrolling |
| Primary completion | 2032-12-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis
Interventions
- Drug: Diroximel Fumarate — also filed as VUMERITY, BIIB098
- Drug: Dimethyl Fumarate — also filed as Tecfidera, DMF, BG00012
- Drug: Disease-Modifying Therapies (DMTs)
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Confirmed Serious Adverse Events (SAEs) in the Vumerity, Tecfidera, Other Selected DMTs (Teriflunomide, Beta-interferons, or Glatiramer Acetate), or Vumerity/Tecfidera Switch Cohorts
measured Up to 10 years
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed